Complex EGFR mutations with T790M and a shorter treatment duration of previous EGFR-TKIs have been associated with shorter PFS and OS in patients with advanced NSCLC treated with osimertinib [56]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.